SlideShare una empresa de Scribd logo
1 de 39
The Microbiome in COPD
Progress and Pitfalls
Sanjay Sethi MD
Professor of Medicine
Division Chief, Pulmonary, Critical Care and
Sleep Medicine
Assistant Vice President for Health Sciences
University at Buffalo, SUNY
ssethi@buffalo.edu
British Hypothesis
 Mucus Hypersecretion
 Infective
exacerbations
Fletcher and Peto BMJ 1977,1:1645-8
Ciba Guest Symposium 1959,
Thorax;14:286-99
Learning Objectives
 Does the lung microbiome change in Stable
COPD?
 Does the lung microbiome impact disease
progression in COPD?
 Does the lung microbiome change at
Exacerbation and with its treatment?
 Does conventional microbiology have a role
in the microbiome era?
Learning Objectives
 Does the lung microbiome change in Stable
COPD?
 Does the lung microbiome impact disease
progression in COPD?
 Does the lung microbiome change at
Exacerbation and with its treatment?
 Does conventional microbiology have a role
in the microbiome era?
Microbiome Diversity in COPD
Cabrera-Rubio J Clin Micro 2012; 50 (11):3562
 Six former smokers with
moderate COPD
 No controls
 Sputum, BAL, Bronchial biopsy
and Bronchial aspirates obtained
Microbiome diversity in COPD
Erb-Downward et al PLoS ONE 6(2): e16384.
Tissue microbiome in COPD
Sze et al AJRCCM 2012,185:1073-80
Are these Upper or Lower Airway
Samples?
Hilty et al, Plos ONE 5 (1): e58578
Erb-Downward et al PLoS ONE 6(2): e16384.
Bacterial Colonization
in Ex-smokers with COPD
Group % positive for PPM
>/=102/ml
Pathogens isolated Titer
1 (ex-smokers with
COPD)
34.6 % (9/26) 1) NTHI and HP
2) NTHI and SP
3) HP
4) PA
5) SA
6) NTHI
7) NTHI
8) HP
9) HP
3 x 102 2 x 102
7 x 104 2 x 104
1 x 102
6 x 102
1 x 102
1.5 x 104
5 x 105
6.5 x 105
3 x 105
2 (ex-smokers
without COPD)
0% (0/20)
3 (healthy non-
smokers)
6.7% (1/15) 1) HP 2 x 102
Sethi et al AJRCCM 2006, 173:991-8
• A sequential two-scope procedure was performed
• The right middle lobe was lavaged with 50 x 3 ml of
saline.
Endotoxin levels in BAL in COPD
Sethi et al AJRCCM 2006, 173:991-8
Contamination of Lower Airway Specimens
Sethi et al AJRCCM 2006, Charlson et al AJRCCM 2011
Unless measures are taken
- to avoid scope contamination
and
- control for environmental
contamination
- the results of Bronchoscopic
microbiome studies are
uninterpretable
Does the Lung Microbiome change
in Stable COPD?
 Yes, by conventional microbiology
 Current microbiome studies are inadequate
 Increase in Proteobacteria
 Decrease in Diversity
 Similar Community structure changes are
seen in Bronchiectasis and Cystic Fibrosis
Learning Objectives
 Does the lung microbiome change in Stable
COPD?
 Does the lung microbiome impact disease
progression in COPD?
 Does the lung microbiome change at
Exacerbation and with its treatment?
 Does conventional microbiology have a role
in the microbiome era?
Bacterial Colonization
in Ex-smokers with COPD
Group % positive for PPM
>/=102/ml
Pathogens isolated Titer
1 (ex-smokers with
COPD)
34.6 % (9/26) 1) NTHI and HP
2) NTHI and SP
3) HP
4) PA
5) SA
6) NTHI
7) NTHI
8) HP
9) HP
3 x 102 2 x 102
7 x 104 2 x 104
1 x 102
6 x 102
1 x 102
1.5 x 104
5 x 105
6.5 x 105
3 x 105
2 (ex-smokers
without COPD)
0% (0/20)
3 (healthy non-
smokers)
6.7% (1/15) 1) HP 2 x 102
Sethi et al AJRCCM 2006, 173:991-8
• A sequential two-scope procedure was performed
• The right middle lobe was lavaged with 50 x 3 ml of
saline.
0
10
20
30
40
50
60
70
80
90
COPD
PPB+
COPD
PPB-
Ex-smokers Non-smokers
%PMN
Groups
p<0.001
p<0.001
p=0.03
p=0.02
p=0.004
0
50000
100000
150000
200000
250000
300000
350000
400000
450000
PMN/ml
p=0.02
p=0.007
p<0.001
COPD
PPB+
COPD
PPB-
Ex-smokers Non-smokers
Groups
Sethi S et al Am J Resp Crit Care Med 2006;173:991-8.
PMN, polymorphonuclear neutrophil; PBB, potentially pathogenic bacteria, including Haemophilus spp, Streptococcus
pneumoniae, Moraxella catarrhalis, Staphylococcus aureus, Pseudomonas aeruginosa, and Gram-negative enteric bacteria
Bacterial Colonization and Airway
Inflammation in Ex-smokers with COPD
Groups Groups
1
10
100
1000
IL-8pg/ml
p=0.006
p<0.001
p<0.001
p=0.02
1
10
100
1000
10000
100000
1000000
ActiveMMP-9units/ml
p=0.04
p<0.001
p=0.01
p=0.002
p=0.007
IL-8, interleukin 8; MMP-9, matrix metalloproteinase-9
Bacterial Colonization and Airway
Inflammation in Ex-smokers with COPD
COPD
PPB+
COPD
PPB-
Ex-smokers Non-smokers COPD
PPB+
COPD
PPB-
Ex-smokers Non-smokers
Sethi S et al Am J Resp Crit Care Med 2006;173:991-8.
Greater Induction of Cytokines by
Proteobacteria from Dendritic Cells
Larsen et al, PLoS ONE 2012, 7(2): e31976
Potential Consequences of Altered
Airway Microbiome in COPD
Hogg et al, NEJM 2004, Martínez-García et al. Chest 2011
Vicious Circle Hypothesis
Initiating factors
e.g. smoking, childhood respiratory disease
Impaired innate
lung defense
Microbial
Colonization
Airway
epithelial injury
Inflammatory
response
Increased proteolytic
activity
Altered proteinase
anti-proteinase
balance
Progression of
COPD
Bacterial
products
Acute
Exacerbation
Sethi and Murphy NEJM 2008
Learning Objectives
 Does the lung microbiome change in Stable
COPD?
 Does the lung microbiome impact disease
progression in COPD?
 Does the lung microbiome change at
Exacerbation and with its treatment?
 Does conventional microbiology have a role
in the microbiome era?
COPD Study Clinic
 Aims
 Dynamics of bacterial
infection in COPD
 Hypothesis
 Acquisition of new
strains of bacterial
pathogens is
associated with an
increased risk of
exacerbation
 Clinic visits:
 Monthly
 Suspected exacerbation
 At each visit:
 Clinical evaluation
 Serum sample
 Sputum sample for
quantitative
bacteriology
Naturally Occurring Exacerbations:
Changes in the Microbiome
-150 -100 -50 0 50 100 150
Days Relative to Exacerbation
Exacerbationonset
Antibiotics only
Corticosteroids only
Antibiotics and
corticosteroids
Exacerbation treatment group
Huang et al, JCM, J Clin Microbiol. 2014 ;52(8):2813-23
Changes in Microbiome at
Exacerbation
Huang et al, JCM, J Clin Microbiol. 2014 ;52(8):2813-23
Bacterial Families Hang out Together
Le
ntisp
ha
erae
En
teroba
cteriace
ae
Ve
rru
co
micro
bia
Ve
rru
co
micro
bia su
bd
ivision 5
LD
1P
A grou
p
Ch
lamyd
iace
ae
Pa
rach
lamyd
iace
ae
WS3
un
cla
ssifie
d
BR
C1
C
ald
ith
rix
Aquifi
ca
e
G
em
m
at
im
ona
de
te
s
G
em
m
at
im
on
ad
et
es
Clo
stridia
ceae
Clo
stridia
ceae
Clo
stridia
ceae
Clo
stridiacea
e
Clostridiacea
e
Clostridiacea
e
Clostridiaceae
ClostridiaceaeClostridiaceaeClostrid
iace
ae
LachnospiraceaeLachnospiraceaeLachnospiraceaeLachnospiraceaeLachnospiraceaeLachnospiraceae
gutclo
ne
gro
up
gutclo
ne
gro
upCa
tab
acterCa
tab
acter
LachnospiraceaeLachnospiraceae
Lachnospiraceae
Lachnospiraceae
Lachnospiraceae
Lachnospiraceae
Lachnospiraceae
Lachnospiraceae
Lachnospiraceae
Lachnospiraceae
Lachnospiraceae
Lachnospiraceae
Lachnospiraceae
Lachnospiraceae
Lachnospiraceae
Lachnospiraceae
LachnospiraceaeLachnospiraceaeLachnospiraceaeLachnospiraceae
Aer
oc
oc
ca
ce
ae
Aer
oc
oc
ca
ce
ae
Ae
ro
co
cc
ac
ea
e
Car
no
ba
cter
iace
ae
Ae
ro
co
cc
ac
ea
e
En
teroco
cc
ac
ea
e
En
teroco
cc
ac
ea
e
En
teroco
ccac
ea
e
En
teroco
ccac
ea
e
En
teroco
ccac
ea
e
En
ter
ococcaceae
En
teroco
cc
ac
ea
e
En
teroco
cc
ac
ea
e
En
teroco
cc
ac
ea
e
Lacto
bacillac
eae
Lacto
bacillaceae
Lacto
bacillaceae
Lacto
bacillaceae
Lacto
bacillaceae
Lacto
bacillace
ae
Lactobacillace
ae
Lac
tob
acillac
eae
Lac
tobacillac
eae
Lac
tobacillaceae
Lac
tobacillaceae
Lac
tobacillace
ae
Leuconostoc
aceae
Le
ucon
ostoc
aceae
Stre
ptoc
occaceae
Streptococcaceae
Streptococcaceae
Streptococcaceae
Streptococcaceae
Streptococcaceae
Streptococcaceae
Streptococcaceae
Streptococcaceae
Streptococcaceae
Streptococca
ceae
Streptococca
ceae
Streptococcaceae
Strep
tococcaceae
Streptococcaceae
Streptococcacea
e
Bac
illi
Stre
ptococcaceae
Pa
eniba
cillac
eae
Sp
oro
lac
tob
acilla
ceae
Ca
ryo
phanaceae
Ba
cillac
ea
e
Ba
cillac
ea
e
Ba
cillac
ea
e
Ba
cillac
ea
e
Ba
cillace
ae
Bac
illac
ea
e
Bac
illac
ea
e
Bac
illac
ea
e
Bac
illac
ea
e
Bac
illac
ea
e
Bac
illac
ea
e
Bac
illac
ea
e
Bac
illac
ea
e
Bac
illac
ea
e
Bac
illac
ea
e
Bac
illac
ea
e
Baci
lla
ce
ae
Baci
lla
ce
ae
Sta
ph
yloc
oc
ca
ce
ae
Sta
ph
yloc
oc
ca
ce
ae
Sta
ph
yloc
oc
ca
ce
ae
Sta
ph
yloc
oc
ca
ce
ae
Sta
ph
yloc
oc
ca
ce
ae
Sta
ph
yloc
oc
ca
ce
ae
Sta
ph
yloc
oc
ca
ce
aeSta
ph
yloc
oc
ca
ce
ae
Sta
ph
yloc
oc
ca
ce
ae
Baci
lla
ce
ae
Ha
loba
cillace
ae
Ha
loba
cillace
aeBa
cilla
ce
ae
Ba
cilla
ce
ae
Bac
illac
ea
e
Ba
cilla
ce
ae
Ha
loba
cilla
ce
ae
Fus
oba
cteriac
eae
Mycop
lasmataceae
Acholeplasmataceae
Ery
sipelotric
haceae
Ery
sipelo
tric
haceae
Erysipe
lotrichaceae
Erysipe
lotrichaceae
Clostridiaceae
Clostridiaceae
Clostridiaceae
Clostridiaceae
Clostridiaceae
ClostridiaceaePeptostreptococcaceaePeptostreptococcaceaePeptostreptococcaceae
ClostridiaceaeClostridiaceaeClostridiaceaePeptostreptococcaceae
ClostridiaceaeClostridiaceaePeptostreptococcaceae
Peptostreptoco
ccaceae
Peptostreptoco
ccaceae
Pep
tostrep
tococcaceae
Pep
tostrep
tococcaceae
Peptostre
ptococ
cac
eae
Pe
ptoc
oc
c/Ac
idam
inoc
oc
c
Pe
ptoc
c/A
cid
am
ino
co
cc
Pe
ptococ
c/A
cid
am
ino
co
cc
Pe
ptoc
oc
c/A
cid
am
ino
co
cc
Pe
pto
cc/Acid
am
ino
cocc
Pe
pto
cc/Acid
am
ino
cocc
Firm
icutes
Natrono
an
ae
robium
Sy
mbiob
ac
teria
Ba
cillace
ae
Firm
icu
tes
Pol
ya
ng
ia
ce
ae
Pol
ya
ng
ia
ce
ae
Pol
ya
ng
ia
ce
ae
Pol
ya
ng
ia
ce
ae
Pol
ya
ng
ia
ce
ae
Delta
pr
ot
eo
ba
cter
ia
Delta
pr
ot
eo
ba
cter
ia
Delta
pr
ot
eo
ba
cter
ia
Del
ta
pr
ot
eo
ba
cter
ia
Delta
pr
ot
eo
ba
cter
ia
Des
ulfoba
cter
ac
ea
e
Syn
tro
ph
ac
ea
e
Deltaproteo
ba
cteria
Des
ulfobu
lbac
ea
e
De
su
lfo
bu
lbac
ea
e
De
su
lfo
bu
lbac
ea
e
Des
ulfoba
cter
ac
ea
e
Deltaproteo
ba
cteria
D
esu
lfu
ro
m
onace
ae
G
eob
ac
te
ra
ce
ae
Syn
trop
ho
ba
ct
er
ac
ea
e
Del
ta
pr
ot
eo
ba
ct
er
ia
Syn
trop
ho
ba
ct
er
ac
ea
e
Del
ta
pr
ot
eo
ba
ct
er
iaD
elta
pro
te
obact
eria
De
su
lfo
ha
lobiac
ea
e
De
su
lfo
vib
rio
na
ce
ae
De
su
lfovib
rio
na
ce
ae
Rhodocyclaceae
Nitro
somonadaceae
Betaproteobacteria
Methylophilaceae
Rhodocyclaceae
Rhodocyclaceae
Neisseriaceae
Procabacteriaceae
Burkholderiaceae
Ralstoniaceae
Ralstoniaceae
Ralstoniaceae
Ralstoniaceae
Oxalobacteraceae
Oxalobacteraceae
Oxalobacteraceae
Oxalobacteraceae
Oxalobacteraceae
Oxalobacteraceae
Oxalobacteraceae
Oxalobacteraceae
Burkholderiaceae
Alcaligenaceae
Alcaligenaceae
Alcaligenaceae
Gammaproteobacteria
Xanthomonadaceae
Xanthomonadaceae
Xanthomonadaceae
Xanthomonadaceae
Xanthomonadaceae
Legionellaceae
Moraxellace
ae
Moraxellaceae
Moraxellaceae
Moraxellaceae
Pseud
omona
dac
eae
Pseud
omonadace
ae
Pseudomo
nadaceae
Pseudomo
nadaceae
Pseudomo
nadaceae
Ocean
osp
irilla
cea
e
Pseud
omona
dac
eae
Pis
cirick
ettsia
ceae
Pis
cirick
ettsia
ceae
Ga
mm
aproteobacte
ria
Me
thy
loc
occaceae
Ga
mm
ap
roteob
acter
ia
Ga
mm
ap
roteo
ba
cte
ria
Ga
mm
aproteobacte
ria
Gammaproteobacteria
Halomonadaceae
Alte
ro
m
on
ad
ac
ea
e
Alte
ro
m
on
ad
ac
ea
e
Pse
ud
oa
lte
ro
m
on
ad
ac
ea
e
Alte
ro
m
on
ad
ac
ea
eAl
tero
mon
ad
ac
ea
e
Ps
eu
do
altero
mon
ad
ac
ea
e
Alteromon
ad
ac
ea
e
Alteromon
ad
ac
ea
e
Alteromon
ad
ac
ea
e
Alteromon
ad
ac
ea
e
Alteromon
ad
ac
ea
e
Alteromon
ad
ac
ea
e
Alteromon
ad
ac
ea
e
Al
tero
mon
ad
ac
ea
e
Al
tero
mon
ad
ac
ea
e
Alte
ro
m
on
ad
ac
ea
e
Alte
ro
m
on
ad
ac
ea
e
Alte
ro
m
on
ad
ac
ea
e
Alte
ro
m
on
ad
ac
ea
e
Alte
ro
m
on
ad
ac
ea
e
Alte
ro
m
on
ad
ac
ea
e
Alte
ro
m
on
ad
ac
ea
e
She
wan
ellace
ae
Alte
ro
m
on
ad
ac
ea
e
Alte
ro
m
on
ad
ac
ea
e
G
am
m
ap
ro
te
ob
ac
te
ria
Alte
ro
m
on
ad
ac
ea
e
Alte
ro
m
on
ad
ac
ea
e
Alte
ro
m
on
ad
ac
ea
e
Shew
an
el
la
ce
ae
Shew
anella
ce
ae
Shew
anella
ce
ae
G
am
m
apro
te
obact
eria
Vibriona
ce
ae
Vi
br
iona
ce
ae
Vibrio
na
ce
ae
Vibrio
na
ce
ae
Vibrio
na
ce
ae
Pa
ste
urellacea
e
Pa
ste
urellacea
e
Pa
ste
urellaceae
Pa
ste
urellacea
e
Pa
ste
ure
llaceae
Pa
ste
ure
llaceae
Paste
ure
llac
eae
Paste
ure
llac
eae
Paste
ure
llac
eae
Pa
ste
ure
llaceae
Pa
ste
ure
llaceae
Enterobac
teriace
ae
Enterobac
teriace
ae
Enterobacteriaceae
Enterobacteriaceae
EnterobacteriaceaeEnterobacteriaceaeEnterobacteriaceaeEnterobacteriaceaeEnterobacteriaceae
Enterobacteriaceae
Enterobacteriaceae
Enterobacteriaceae
Enterobacteriaceae
Enterobacteriaceae
Enterobacteriaceae
Enterobacteriaceae
Enterobacteriaceae
Enterobacteriaceae
Enterobacteriaceae
Enterobacteriaceae
Enterobacteriaceae
Enterobacteriaceae
Enterobacteriaceae
Enterobacteriaceae
Enterobacteriaceae
Enterobacteriaceae
Enterobacteria
ceae
Enterobacteriaceae
Enterobacteriaceae
Enterobacteriacea
e
Ente
roba
cteriaceae
Enterobacteria
ceae
Enterobacteriaceae
Enterobacteriaceae
Enterobac
teriace
ae
Enterobac
teriace
ae
Gammaproteobacteria
Enterobacteriaceae
Enterobacteriaceae
Enterobacteriaceae
Enterobacteriaceae
Enterobacteriaceae
Enterobacteriaceae
Enterob
acte
riaceae
Enterob
acte
riaceae
Ente
roba
cteriaceae
Enterobacteriaceae
Enterobacteria
ceaeEnterobacteriaceaeEnterobacteriaceaeEnterobacteriaceae
Enterobacteriaceae
Ente
robacteriaceae
Enterobacteria
cea
e
Entero
bac
teriace
ae
X6
04
12
.2
Ae
romon
ad
ac
ea
e
Ae
romon
ad
ac
ea
e
S3
92
32
.2
Ae
romon
ad
ac
ea
e
Ae
romon
ad
ac
ea
e
Ch
romatiac
ea
e
Gammaproteobacteria
Coxiellaceae
Coxiellaceae
Coxiellaceae
Thiotrichaceae
Thiotrichaceae
Chromatiaceae
Gam
map
roteobacteria
Ro
seococcaceae
Alph
ap
roteo
ba
cte
ria
Rickettsia
ceae
Rickettsia
ceae
Ca
ediba
cte
rac
eae
Alp
hapro
teo
bacte
ria
Alp
hapro
teo
bacte
ria
Rhodocyclaceae
Caulobac
terace
ae
Caulobac
tera
cea
e
Cau
lobacteraceae
Cau
loba
cteraceaeCaulobactera
cea
e
Alp
hapro
teo
bacte
ria
Bra
dyrhizobiaceae
Bra
dyrhizobiaceae
Ac
idob
ac
teria
Acido
ba
cter
iace
ae
Acido
ba
cter
iace
ae
Acido
ba
cter
iace
ae
Acido
ba
cter
iace
ae
Acido
ba
cter
ia
Acido
ba
cter
iace
ae
Acido
ba
cter
ia
ce
ae
Nitros
pina
ce
ae
Ac
idob
ac
teria
ce
ae
Ac
idob
ac
teria
De
lta
proteo
ba
cteria
De
lta
proteo
ba
cteria
NC
10
−2Un
cla
ss
ifie
d
Leptospiraceae
Leptospiraceae
Spirochaetaceae
Spirochaetaceae
Spirochaetaceae
Spirochaetaceae
Spirochaetaceae
Spirochaetaceae
Chlorobi
Cren
otrichace
ae
Ba
cte
roide
tes
Ba
cte
roide
tes
Sp
hin
go
ba
cte
ria
Ba
cte
roide
tes
Ba
cte
roide
tes
Ba
cte
roidetes
Ba
cte
roidetes
Ba
cte
roide
tes
Rik
enella
cea
e
Bacte
roidetes
Porph
yro
mo
nadaceae
Ba
cte
roidaceae
Ba
cte
roidaceae
Bacteroid
etes
Bacteroid
ete
s
Flavob
acteria
ceae
Flavob
acteria
cea
e
Blattab
acteria
cea
e
SphingobacteriaFlex
ibac
teraceae
Flam
meo
virgaceae
Flexiba
cteraceae
CrenotrichaceaeCrenotrich
aceaeCrenotrichaceaeCren
otrichace
ae
Helicobacteraceae
Helicobacteraceae
Epsilonproteobacteria
Helicobacteraceae
Campylobacteraceae
mgA−2
mgA−1
TM7−3
CyanobacteriaChloroplasts
Chloroplasts
Chloroplasts
Cop
ro
th
er
m
ob
ac
te
ria
Syn
er
gi
st
es
Syn
er
gi
st
es
Syn
er
gist
es
Syn
er
gi
stesOP9
Deh
aloc
oc
co
idet
es
Deh
aloc
oc
co
idetes
Deh
aloc
oc
co
idetes
Ana
er
olinea
e
Chlor
of
lexi
Cellulom
on
ad
ac
ea
e
M
icro
co
cc
ac
ea
e
M
icro
co
cc
ac
ea
e
Acido
ba
ct
er
ia
Act
in
om
yc
et
ac
ea
e
Bifido
ba
ct
er
ia
ce
ae
Bifido
ba
ct
er
ia
ce
ae
Bifi
do
ba
ct
er
ia
ce
ae
Acido
ba
cter
ia
Acido
ba
cter
ia
Cor
ioba
cter
iace
ae
Rub
ro
ba
cter
ac
ea
e
Ac
idob
ac
teria
0.01
Classes (tree branches):
Gammaproteobacteria
Verrucomicrobiae
Chlamydiae
Aquificae
gut clone group
Catabacter
Bacilli
Fusobacteria
Mollicutes
Symbiobacteria
Deltaproteobacteria
Betaproteobacteria
Alphaproteobacteria
Acidobacteria
N C 10− 2
Spirochaetes
Sphingobacteria
Bacteroidetes
Flavobacteria
Epsilonproteobacteria
m gA − 1
T M 7− 3
Cyanobacteria
OP9
Actinobacteria
Enterobacteriaceae
Pasteurellaceae
(Haemophilus-related)
Pseudomonadaceae
Moraxellaceae
Oxalobacteraceae (Betaproteobacteria)
Lactobacillus spp.
Streptococcaceae
(Lactobacillales)
Helicobacter
Campylobacter
(Epsilonproteobacteria)
Deltaproteobacteria
Staphylococcus spp.
Clostridiaceae/Lachnospiraceae (Clostridia)
Bacillaceae
Abundance
Higher Lower
Positive correlation
Negative correlation
Huang et al, JCM, J Clin Microbiol. 2014 ;52(8):2813-23
Antibiotics and Steroids have Differential Effects
on the Microbiome in AECOPD
Positive changes in relative abundance (log2) indicate an
increase in the latter time point compared.
Huang et al, JCM, J Clin Microbiol. 2014 ;52(8):2813-23
MAESTRAL Study: Clinical Failure Rates with Oral
Corticosteroid use
0
5
10
15
20
25
30
35
40
During therapy EOT 4 weeks post-
therapy
8 weeks post-
therapy
Clinicalfailure(%ofpatients)
Sethi et al, Infection 2016
Changes in Airway Microbiome
after Rhinovirus inoculation
Molyneaux; et al, Am J Respir Crit Care Med 188, 1224-1231.
*P < 0.001
Control: no significant
differences
Distribution of bacterial phyla at each time
point after rhinovirus (RV) inoculation.
Molyneaux et al, Am J Respir Crit Care Med 188, 1224-1231.
COPD: significant increases in
Proteobacteria (dark blue)
were observed on Day 15 (P =
2.2 × 10–16).
Bacterial Load (16s) and Inflammatory
Changes following Rhinovirus Infection
Molyneaux et al, Am J Respir Crit Care Med 188, 1224-1231.
p=0.08
p=0.0001
p=0.007
p=0.045p=0.001
p=0.07
Learning Objectives
 Does the lung microbiome change in Stable
COPD?
 Does the lung microbiome impact disease
progression in COPD?
 Does the lung microbiome change at
Exacerbation and with its treatment?
 Does conventional microbiology have a role
in the microbiome era?
TMI
Losing the Trees in the Forest
Species vs Strain level Differentiation
Han et al Thorax 2013 Sethi et al NEJM 2008
NTHI Colonization vs Exacerbation
strains
•10 exacerbation strains
•7 colonization strains
•In vivo mouse model
•In vitro respiratory
epithelial cell line
Chin et al AJRCCM 2005
Does Conventional Microbiology have
a Role in the Microbiome Era?
 Identifying a pathogen by sequence is the
first step
 Immune and inflammatory consequences of
putative pathogens need to be determined
 Ability to manipulate the pathogen in
culture is essential
 Vaccine development
 Pathogen virulence
Conclusions
 The ability to assess the lung microbiome could
radically change our understanding of lung
disease and lung infection
 COPD and COPD exacerbations are clearly
associated with changes in the lung
microbiome
 Restoring the healthy lung microbiome could
make a significant difference in COPD
management
 Maybe, the British were right all the time!
Acknowledgments
 Co-Investigators
 Tim Murphy
 Charles Berenson
 Karin Provost
 Ilya Berim
 Study coordinators
 Nancy Evans
 Karen Eschberger
 Jane Maloney
 Ellana Eberhardt
 Laboratory personnel
 Catherine Wrona
 Lori Grove
 Phyllis Lobbins
 Regina Clare
 Collaborators
 Yvonne Huang (UCSF)
 U of Iowa
BRN Symposium 03/06/16 Microbiome in COPD: Pitfalls and Progress

Más contenido relacionado

La actualidad más candente

03 BRN Research Forum Bronquiectasias. Parte III por Oriol Sibila
03 BRN Research Forum Bronquiectasias. Parte III por Oriol Sibila03 BRN Research Forum Bronquiectasias. Parte III por Oriol Sibila
03 BRN Research Forum Bronquiectasias. Parte III por Oriol Sibilabrnmomentum
 
Case report :systemic torulopsis after gastric bypass operation
Case report :systemic torulopsis after gastric bypass operationCase report :systemic torulopsis after gastric bypass operation
Case report :systemic torulopsis after gastric bypass operationAhmed Bahnassy
 
Candida in icu and diagnosis DR M.L. PRASHANTH MD IDCCM
Candida in icu and diagnosis DR M.L. PRASHANTH MD IDCCM Candida in icu and diagnosis DR M.L. PRASHANTH MD IDCCM
Candida in icu and diagnosis DR M.L. PRASHANTH MD IDCCM Prashanth Manipadaga Lakshmi
 
invasive Fungal dis 2012
 invasive Fungal dis  2012 invasive Fungal dis  2012
invasive Fungal dis 2012ahmed saad
 
Cefditoren pivoxil: a new antibiotic for the treatment of respiratory infections
Cefditoren pivoxil:a new antibiotic for the treatment of respiratory infectionsCefditoren pivoxil:a new antibiotic for the treatment of respiratory infections
Cefditoren pivoxil: a new antibiotic for the treatment of respiratory infectionsJordi Roig
 
Recurrent uti without obvious risk factors
Recurrent uti without obvious risk factorsRecurrent uti without obvious risk factors
Recurrent uti without obvious risk factorsPediatric Nephrology
 
Seminario biologia molecular Sara Gonzalez
Seminario biologia molecular Sara GonzalezSeminario biologia molecular Sara Gonzalez
Seminario biologia molecular Sara GonzalezSaraGonzalez195
 
Fungal infections in critical care(cases)
Fungal infections in critical care(cases)Fungal infections in critical care(cases)
Fungal infections in critical care(cases)fungalinfection
 
Microbiome & Infection Control - NJ Fawcett
Microbiome & Infection Control - NJ FawcettMicrobiome & Infection Control - NJ Fawcett
Microbiome & Infection Control - NJ FawcettNicola Fawcett
 
Hepatitis B (Nepal senario)
Hepatitis B (Nepal senario) Hepatitis B (Nepal senario)
Hepatitis B (Nepal senario) Sof2050
 
Invasive fungal infection in icu
Invasive fungal infection in icuInvasive fungal infection in icu
Invasive fungal infection in icupulmonary medicine
 
Bacterial infections in cirrhosis
Bacterial infections in cirrhosisBacterial infections in cirrhosis
Bacterial infections in cirrhosisMario Mondelli
 
Le infezioni nel cirrotico: aspetti clinici - Gastrolearning®
Le infezioni nel cirrotico: aspetti clinici - Gastrolearning®Le infezioni nel cirrotico: aspetti clinici - Gastrolearning®
Le infezioni nel cirrotico: aspetti clinici - Gastrolearning®Gastrolearning
 
Diagnostics of tuberculosis: An insight into Genexpert 27 4-15
Diagnostics of tuberculosis: An insight into Genexpert 27 4-15Diagnostics of tuberculosis: An insight into Genexpert 27 4-15
Diagnostics of tuberculosis: An insight into Genexpert 27 4-15Yahya Noori, Ph.D
 
Esbl 2012-transmissão-cid
Esbl 2012-transmissão-cidEsbl 2012-transmissão-cid
Esbl 2012-transmissão-ciddeandreazzi
 
Treatment of Legionnaires’ Disease
Treatment of Legionnaires’ DiseaseTreatment of Legionnaires’ Disease
Treatment of Legionnaires’ DiseaseJordi Roig
 
Fungal infections in hematology patients: advances in prophylaxis and treatment
Fungal infections in hematology patients: advances in prophylaxis and treatmentFungal infections in hematology patients: advances in prophylaxis and treatment
Fungal infections in hematology patients: advances in prophylaxis and treatmentspa718
 
Bohomolets Oncology Lecture year 5
Bohomolets Oncology Lecture year 5Bohomolets Oncology Lecture year 5
Bohomolets Oncology Lecture year 5Dr. Rubz
 

La actualidad más candente (20)

03 BRN Research Forum Bronquiectasias. Parte III por Oriol Sibila
03 BRN Research Forum Bronquiectasias. Parte III por Oriol Sibila03 BRN Research Forum Bronquiectasias. Parte III por Oriol Sibila
03 BRN Research Forum Bronquiectasias. Parte III por Oriol Sibila
 
Case report :systemic torulopsis after gastric bypass operation
Case report :systemic torulopsis after gastric bypass operationCase report :systemic torulopsis after gastric bypass operation
Case report :systemic torulopsis after gastric bypass operation
 
Candida in icu and diagnosis DR M.L. PRASHANTH MD IDCCM
Candida in icu and diagnosis DR M.L. PRASHANTH MD IDCCM Candida in icu and diagnosis DR M.L. PRASHANTH MD IDCCM
Candida in icu and diagnosis DR M.L. PRASHANTH MD IDCCM
 
invasive Fungal dis 2012
 invasive Fungal dis  2012 invasive Fungal dis  2012
invasive Fungal dis 2012
 
Cefditoren pivoxil: a new antibiotic for the treatment of respiratory infections
Cefditoren pivoxil:a new antibiotic for the treatment of respiratory infectionsCefditoren pivoxil:a new antibiotic for the treatment of respiratory infections
Cefditoren pivoxil: a new antibiotic for the treatment of respiratory infections
 
Recurrent uti without obvious risk factors
Recurrent uti without obvious risk factorsRecurrent uti without obvious risk factors
Recurrent uti without obvious risk factors
 
Seminario biologia molecular Sara Gonzalez
Seminario biologia molecular Sara GonzalezSeminario biologia molecular Sara Gonzalez
Seminario biologia molecular Sara Gonzalez
 
Fungal infections in critical care(cases)
Fungal infections in critical care(cases)Fungal infections in critical care(cases)
Fungal infections in critical care(cases)
 
Complicated uti
Complicated uti Complicated uti
Complicated uti
 
Microbiome & Infection Control - NJ Fawcett
Microbiome & Infection Control - NJ FawcettMicrobiome & Infection Control - NJ Fawcett
Microbiome & Infection Control - NJ Fawcett
 
Hepatitis B (Nepal senario)
Hepatitis B (Nepal senario) Hepatitis B (Nepal senario)
Hepatitis B (Nepal senario)
 
Invasive fungal infection in icu
Invasive fungal infection in icuInvasive fungal infection in icu
Invasive fungal infection in icu
 
Bacterial infections in cirrhosis
Bacterial infections in cirrhosisBacterial infections in cirrhosis
Bacterial infections in cirrhosis
 
Le infezioni nel cirrotico: aspetti clinici - Gastrolearning®
Le infezioni nel cirrotico: aspetti clinici - Gastrolearning®Le infezioni nel cirrotico: aspetti clinici - Gastrolearning®
Le infezioni nel cirrotico: aspetti clinici - Gastrolearning®
 
Diagnostics of tuberculosis: An insight into Genexpert 27 4-15
Diagnostics of tuberculosis: An insight into Genexpert 27 4-15Diagnostics of tuberculosis: An insight into Genexpert 27 4-15
Diagnostics of tuberculosis: An insight into Genexpert 27 4-15
 
Esbl 2012-transmissão-cid
Esbl 2012-transmissão-cidEsbl 2012-transmissão-cid
Esbl 2012-transmissão-cid
 
Treatment of Legionnaires’ Disease
Treatment of Legionnaires’ DiseaseTreatment of Legionnaires’ Disease
Treatment of Legionnaires’ Disease
 
Fungal infections in hematology patients: advances in prophylaxis and treatment
Fungal infections in hematology patients: advances in prophylaxis and treatmentFungal infections in hematology patients: advances in prophylaxis and treatment
Fungal infections in hematology patients: advances in prophylaxis and treatment
 
Bohomolets Oncology Lecture year 5
Bohomolets Oncology Lecture year 5Bohomolets Oncology Lecture year 5
Bohomolets Oncology Lecture year 5
 
Candidiasis immunity
Candidiasis immunityCandidiasis immunity
Candidiasis immunity
 

Similar a BRN Symposium 03/06/16 Microbiome in COPD: Pitfalls and Progress

Gut Microbiota in Lung Cancer_Indrawaty_Gizi.pdf
Gut Microbiota in Lung Cancer_Indrawaty_Gizi.pdfGut Microbiota in Lung Cancer_Indrawaty_Gizi.pdf
Gut Microbiota in Lung Cancer_Indrawaty_Gizi.pdfIndahUdin1
 
Biologics for COPD — Finally Here.pptx
Biologics for COPD —   Finally Here.pptxBiologics for COPD —   Finally Here.pptx
Biologics for COPD — Finally Here.pptxsachinkulkarni686020
 
2250-Presentation+III-LindaMeAHand
2250-Presentation+III-LindaMeAHand2250-Presentation+III-LindaMeAHand
2250-Presentation+III-LindaMeAHandJennifer Vo
 
Antibiotic in COPD.ppt
Antibiotic in COPD.pptAntibiotic in COPD.ppt
Antibiotic in COPD.pptSubhajit Ghosh
 
Plan presentation on copd ………………………………….
Plan presentation on copd ………………………………….Plan presentation on copd ………………………………….
Plan presentation on copd ………………………………….Roop
 
COPD First Session
COPD First SessionCOPD First Session
COPD First SessionGamal Agmy
 
Pharmacotherapy of Chronic Obstructive Pulmonary Disease (COPD)
Pharmacotherapy of Chronic Obstructive Pulmonary Disease (COPD)Pharmacotherapy of Chronic Obstructive Pulmonary Disease (COPD)
Pharmacotherapy of Chronic Obstructive Pulmonary Disease (COPD)Arvind Kumar
 
COPD Journal Club
COPD Journal ClubCOPD Journal Club
COPD Journal ClubJade Abudia
 
Respond to this discussion . Add some facts with at least 2 cita.docx
Respond to this discussion . Add some facts with at least 2 cita.docxRespond to this discussion . Add some facts with at least 2 cita.docx
Respond to this discussion . Add some facts with at least 2 cita.docxcwilliam4
 
Macrolide effects on the prevention of copd exacerb
Macrolide effects on the prevention of copd exacerbMacrolide effects on the prevention of copd exacerb
Macrolide effects on the prevention of copd exacerbguidep
 
Debate on mucolytics
Debate on mucolyticsDebate on mucolytics
Debate on mucolyticsPrem Chand
 
Αντιβιοτικά και μικροβίωμα εντέρου - peptiko.gr
Αντιβιοτικά και μικροβίωμα εντέρου - peptiko.grΑντιβιοτικά και μικροβίωμα εντέρου - peptiko.gr
Αντιβιοτικά και μικροβίωμα εντέρου - peptiko.grChristos Zavos, MD, PhD, FEBGH
 
International Journal of Pharmaceutical Science Invention (IJPSI)
International Journal of Pharmaceutical Science Invention (IJPSI)International Journal of Pharmaceutical Science Invention (IJPSI)
International Journal of Pharmaceutical Science Invention (IJPSI)inventionjournals
 
Respiratory disorder and periodontitis
Respiratory disorder and periodontitisRespiratory disorder and periodontitis
Respiratory disorder and periodontitisDr. Vartika Srivastava
 

Similar a BRN Symposium 03/06/16 Microbiome in COPD: Pitfalls and Progress (20)

Gut Microbiota in Lung Cancer_Indrawaty_Gizi.pdf
Gut Microbiota in Lung Cancer_Indrawaty_Gizi.pdfGut Microbiota in Lung Cancer_Indrawaty_Gizi.pdf
Gut Microbiota in Lung Cancer_Indrawaty_Gizi.pdf
 
Ann Pharmacother-2003-Dougherty-1247-55
Ann Pharmacother-2003-Dougherty-1247-55Ann Pharmacother-2003-Dougherty-1247-55
Ann Pharmacother-2003-Dougherty-1247-55
 
Biologics for COPD — Finally Here.pptx
Biologics for COPD —   Finally Here.pptxBiologics for COPD —   Finally Here.pptx
Biologics for COPD — Finally Here.pptx
 
PM2012-808260
PM2012-808260PM2012-808260
PM2012-808260
 
2250-Presentation+III-LindaMeAHand
2250-Presentation+III-LindaMeAHand2250-Presentation+III-LindaMeAHand
2250-Presentation+III-LindaMeAHand
 
Antibiotic in COPD.ppt
Antibiotic in COPD.pptAntibiotic in COPD.ppt
Antibiotic in COPD.ppt
 
Plan presentation on copd ………………………………….
Plan presentation on copd ………………………………….Plan presentation on copd ………………………………….
Plan presentation on copd ………………………………….
 
Cough In The Elderly
Cough In The ElderlyCough In The Elderly
Cough In The Elderly
 
COPD First Session
COPD First SessionCOPD First Session
COPD First Session
 
Pharmacotherapy of Chronic Obstructive Pulmonary Disease (COPD)
Pharmacotherapy of Chronic Obstructive Pulmonary Disease (COPD)Pharmacotherapy of Chronic Obstructive Pulmonary Disease (COPD)
Pharmacotherapy of Chronic Obstructive Pulmonary Disease (COPD)
 
COPD Journal Club
COPD Journal ClubCOPD Journal Club
COPD Journal Club
 
Respond to this discussion . Add some facts with at least 2 cita.docx
Respond to this discussion . Add some facts with at least 2 cita.docxRespond to this discussion . Add some facts with at least 2 cita.docx
Respond to this discussion . Add some facts with at least 2 cita.docx
 
Macrolide effects on the prevention of copd exacerb
Macrolide effects on the prevention of copd exacerbMacrolide effects on the prevention of copd exacerb
Macrolide effects on the prevention of copd exacerb
 
Debate on mucolytics
Debate on mucolyticsDebate on mucolytics
Debate on mucolytics
 
COPD.ppt
COPD.pptCOPD.ppt
COPD.ppt
 
Endobronchial TB
Endobronchial TBEndobronchial TB
Endobronchial TB
 
Αντιβιοτικά και μικροβίωμα εντέρου - peptiko.gr
Αντιβιοτικά και μικροβίωμα εντέρου - peptiko.grΑντιβιοτικά και μικροβίωμα εντέρου - peptiko.gr
Αντιβιοτικά και μικροβίωμα εντέρου - peptiko.gr
 
International Journal of Pharmaceutical Science Invention (IJPSI)
International Journal of Pharmaceutical Science Invention (IJPSI)International Journal of Pharmaceutical Science Invention (IJPSI)
International Journal of Pharmaceutical Science Invention (IJPSI)
 
Respiratory disorder and periodontitis
Respiratory disorder and periodontitisRespiratory disorder and periodontitis
Respiratory disorder and periodontitis
 
Sigma Xi
Sigma XiSigma Xi
Sigma Xi
 

Más de brnmomentum

01_Sogo_Palones_Macías_Tos crónica
01_Sogo_Palones_Macías_Tos crónica01_Sogo_Palones_Macías_Tos crónica
01_Sogo_Palones_Macías_Tos crónicabrnmomentum
 
02_Palones_Cómo medimos la tos en la práctica clínica
02_Palones_Cómo medimos la tos en la práctica clínica02_Palones_Cómo medimos la tos en la práctica clínica
02_Palones_Cómo medimos la tos en la práctica clínicabrnmomentum
 
03_Macías_Impacto de la tos crónica en la calidad de vida de los pacientes
03_Macías_Impacto de la tos crónica en la calidad de vida de los pacientes03_Macías_Impacto de la tos crónica en la calidad de vida de los pacientes
03_Macías_Impacto de la tos crónica en la calidad de vida de los pacientesbrnmomentum
 
04_Crespo_Necesidades no cubiertas en la tos crónica. ¿Hacia dónde vamos?
04_Crespo_Necesidades no cubiertas en la tos crónica. ¿Hacia dónde vamos?04_Crespo_Necesidades no cubiertas en la tos crónica. ¿Hacia dónde vamos?
04_Crespo_Necesidades no cubiertas en la tos crónica. ¿Hacia dónde vamos?brnmomentum
 
05_Palones_Estratificación de la tos crónica en función de la gravedad
05_Palones_Estratificación de la tos crónica en función de la gravedad05_Palones_Estratificación de la tos crónica en función de la gravedad
05_Palones_Estratificación de la tos crónica en función de la gravedadbrnmomentum
 
06_Arismendi_Rol de las Patologías Laríngea y Neurológica
06_Arismendi_Rol de las Patologías Laríngea y Neurológica06_Arismendi_Rol de las Patologías Laríngea y Neurológica
06_Arismendi_Rol de las Patologías Laríngea y Neurológicabrnmomentum
 
05_Maquillón_Ventilación no invasiva en la EPOC: realidad y retos
05_Maquillón_Ventilación no invasiva en la EPOC: realidad y retos05_Maquillón_Ventilación no invasiva en la EPOC: realidad y retos
05_Maquillón_Ventilación no invasiva en la EPOC: realidad y retosbrnmomentum
 
04_Galdeano_Ventilación no invasiva en la EPOC: realidad y retos
04_Galdeano_Ventilación no invasiva en la EPOC: realidad y retos04_Galdeano_Ventilación no invasiva en la EPOC: realidad y retos
04_Galdeano_Ventilación no invasiva en la EPOC: realidad y retosbrnmomentum
 
03 Jessé_Afrontando el uso de biomarcadores en la consulta de EPOC más allá d...
03 Jessé_Afrontando el uso de biomarcadores en la consulta de EPOC más allá d...03 Jessé_Afrontando el uso de biomarcadores en la consulta de EPOC más allá d...
03 Jessé_Afrontando el uso de biomarcadores en la consulta de EPOC más allá d...brnmomentum
 
02_Sara Martí_El microbioma en el paciente con patología grave de la vía aérea
02_Sara Martí_El microbioma en el paciente con patología grave de la vía aérea02_Sara Martí_El microbioma en el paciente con patología grave de la vía aérea
02_Sara Martí_El microbioma en el paciente con patología grave de la vía aéreabrnmomentum
 
01_Faner_Condicionantes genéticos en el desarrollo de EPOC: "Young COPD"
01_Faner_Condicionantes genéticos en el desarrollo de EPOC: "Young COPD"01_Faner_Condicionantes genéticos en el desarrollo de EPOC: "Young COPD"
01_Faner_Condicionantes genéticos en el desarrollo de EPOC: "Young COPD"brnmomentum
 
05_Ausín_Monitorización del tratamiento con fármacos biológicos en asma grave
05_Ausín_Monitorización del tratamiento con fármacos biológicos en asma grave05_Ausín_Monitorización del tratamiento con fármacos biológicos en asma grave
05_Ausín_Monitorización del tratamiento con fármacos biológicos en asma gravebrnmomentum
 
04_Muñoz_Impacto de la contaminación en el asma: estudio comparativo de pobla...
04_Muñoz_Impacto de la contaminación en el asma: estudio comparativo de pobla...04_Muñoz_Impacto de la contaminación en el asma: estudio comparativo de pobla...
04_Muñoz_Impacto de la contaminación en el asma: estudio comparativo de pobla...brnmomentum
 
03_Domingo_Sesión de formación. Presente y futuro en el manejo del asma grave...
03_Domingo_Sesión de formación. Presente y futuro en el manejo del asma grave...03_Domingo_Sesión de formación. Presente y futuro en el manejo del asma grave...
03_Domingo_Sesión de formación. Presente y futuro en el manejo del asma grave...brnmomentum
 
02_Elena Curto_Asma no T2
02_Elena Curto_Asma no T202_Elena Curto_Asma no T2
02_Elena Curto_Asma no T2brnmomentum
 
01_Bobolea_Precision Medicina in Eosinophilic Asthma: an interdisciplinaryu a...
01_Bobolea_Precision Medicina in Eosinophilic Asthma: an interdisciplinaryu a...01_Bobolea_Precision Medicina in Eosinophilic Asthma: an interdisciplinaryu a...
01_Bobolea_Precision Medicina in Eosinophilic Asthma: an interdisciplinaryu a...brnmomentum
 
05 BRN Research Forum BRN Bronquiectasias. Conclusiones por Esther Barreiro
05 BRN Research Forum BRN Bronquiectasias. Conclusiones por Esther Barreiro05 BRN Research Forum BRN Bronquiectasias. Conclusiones por Esther Barreiro
05 BRN Research Forum BRN Bronquiectasias. Conclusiones por Esther Barreirobrnmomentum
 
04 BRN Research Forum Bronquiectasias. Parte IV por David de la Rosa
04 BRN Research Forum Bronquiectasias. Parte IV por David de la Rosa04 BRN Research Forum Bronquiectasias. Parte IV por David de la Rosa
04 BRN Research Forum Bronquiectasias. Parte IV por David de la Rosabrnmomentum
 
02 BRN Research Forum Bronquiectasias. Parte II por Alicia Marín
02 BRN Research Forum Bronquiectasias. Parte II por Alicia Marín02 BRN Research Forum Bronquiectasias. Parte II por Alicia Marín
02 BRN Research Forum Bronquiectasias. Parte II por Alicia Marínbrnmomentum
 
00 BRN Research Forum Bronquiectasias. Introducción por Esther Barreiro
00 BRN Research Forum Bronquiectasias. Introducción por Esther Barreiro00 BRN Research Forum Bronquiectasias. Introducción por Esther Barreiro
00 BRN Research Forum Bronquiectasias. Introducción por Esther Barreirobrnmomentum
 

Más de brnmomentum (20)

01_Sogo_Palones_Macías_Tos crónica
01_Sogo_Palones_Macías_Tos crónica01_Sogo_Palones_Macías_Tos crónica
01_Sogo_Palones_Macías_Tos crónica
 
02_Palones_Cómo medimos la tos en la práctica clínica
02_Palones_Cómo medimos la tos en la práctica clínica02_Palones_Cómo medimos la tos en la práctica clínica
02_Palones_Cómo medimos la tos en la práctica clínica
 
03_Macías_Impacto de la tos crónica en la calidad de vida de los pacientes
03_Macías_Impacto de la tos crónica en la calidad de vida de los pacientes03_Macías_Impacto de la tos crónica en la calidad de vida de los pacientes
03_Macías_Impacto de la tos crónica en la calidad de vida de los pacientes
 
04_Crespo_Necesidades no cubiertas en la tos crónica. ¿Hacia dónde vamos?
04_Crespo_Necesidades no cubiertas en la tos crónica. ¿Hacia dónde vamos?04_Crespo_Necesidades no cubiertas en la tos crónica. ¿Hacia dónde vamos?
04_Crespo_Necesidades no cubiertas en la tos crónica. ¿Hacia dónde vamos?
 
05_Palones_Estratificación de la tos crónica en función de la gravedad
05_Palones_Estratificación de la tos crónica en función de la gravedad05_Palones_Estratificación de la tos crónica en función de la gravedad
05_Palones_Estratificación de la tos crónica en función de la gravedad
 
06_Arismendi_Rol de las Patologías Laríngea y Neurológica
06_Arismendi_Rol de las Patologías Laríngea y Neurológica06_Arismendi_Rol de las Patologías Laríngea y Neurológica
06_Arismendi_Rol de las Patologías Laríngea y Neurológica
 
05_Maquillón_Ventilación no invasiva en la EPOC: realidad y retos
05_Maquillón_Ventilación no invasiva en la EPOC: realidad y retos05_Maquillón_Ventilación no invasiva en la EPOC: realidad y retos
05_Maquillón_Ventilación no invasiva en la EPOC: realidad y retos
 
04_Galdeano_Ventilación no invasiva en la EPOC: realidad y retos
04_Galdeano_Ventilación no invasiva en la EPOC: realidad y retos04_Galdeano_Ventilación no invasiva en la EPOC: realidad y retos
04_Galdeano_Ventilación no invasiva en la EPOC: realidad y retos
 
03 Jessé_Afrontando el uso de biomarcadores en la consulta de EPOC más allá d...
03 Jessé_Afrontando el uso de biomarcadores en la consulta de EPOC más allá d...03 Jessé_Afrontando el uso de biomarcadores en la consulta de EPOC más allá d...
03 Jessé_Afrontando el uso de biomarcadores en la consulta de EPOC más allá d...
 
02_Sara Martí_El microbioma en el paciente con patología grave de la vía aérea
02_Sara Martí_El microbioma en el paciente con patología grave de la vía aérea02_Sara Martí_El microbioma en el paciente con patología grave de la vía aérea
02_Sara Martí_El microbioma en el paciente con patología grave de la vía aérea
 
01_Faner_Condicionantes genéticos en el desarrollo de EPOC: "Young COPD"
01_Faner_Condicionantes genéticos en el desarrollo de EPOC: "Young COPD"01_Faner_Condicionantes genéticos en el desarrollo de EPOC: "Young COPD"
01_Faner_Condicionantes genéticos en el desarrollo de EPOC: "Young COPD"
 
05_Ausín_Monitorización del tratamiento con fármacos biológicos en asma grave
05_Ausín_Monitorización del tratamiento con fármacos biológicos en asma grave05_Ausín_Monitorización del tratamiento con fármacos biológicos en asma grave
05_Ausín_Monitorización del tratamiento con fármacos biológicos en asma grave
 
04_Muñoz_Impacto de la contaminación en el asma: estudio comparativo de pobla...
04_Muñoz_Impacto de la contaminación en el asma: estudio comparativo de pobla...04_Muñoz_Impacto de la contaminación en el asma: estudio comparativo de pobla...
04_Muñoz_Impacto de la contaminación en el asma: estudio comparativo de pobla...
 
03_Domingo_Sesión de formación. Presente y futuro en el manejo del asma grave...
03_Domingo_Sesión de formación. Presente y futuro en el manejo del asma grave...03_Domingo_Sesión de formación. Presente y futuro en el manejo del asma grave...
03_Domingo_Sesión de formación. Presente y futuro en el manejo del asma grave...
 
02_Elena Curto_Asma no T2
02_Elena Curto_Asma no T202_Elena Curto_Asma no T2
02_Elena Curto_Asma no T2
 
01_Bobolea_Precision Medicina in Eosinophilic Asthma: an interdisciplinaryu a...
01_Bobolea_Precision Medicina in Eosinophilic Asthma: an interdisciplinaryu a...01_Bobolea_Precision Medicina in Eosinophilic Asthma: an interdisciplinaryu a...
01_Bobolea_Precision Medicina in Eosinophilic Asthma: an interdisciplinaryu a...
 
05 BRN Research Forum BRN Bronquiectasias. Conclusiones por Esther Barreiro
05 BRN Research Forum BRN Bronquiectasias. Conclusiones por Esther Barreiro05 BRN Research Forum BRN Bronquiectasias. Conclusiones por Esther Barreiro
05 BRN Research Forum BRN Bronquiectasias. Conclusiones por Esther Barreiro
 
04 BRN Research Forum Bronquiectasias. Parte IV por David de la Rosa
04 BRN Research Forum Bronquiectasias. Parte IV por David de la Rosa04 BRN Research Forum Bronquiectasias. Parte IV por David de la Rosa
04 BRN Research Forum Bronquiectasias. Parte IV por David de la Rosa
 
02 BRN Research Forum Bronquiectasias. Parte II por Alicia Marín
02 BRN Research Forum Bronquiectasias. Parte II por Alicia Marín02 BRN Research Forum Bronquiectasias. Parte II por Alicia Marín
02 BRN Research Forum Bronquiectasias. Parte II por Alicia Marín
 
00 BRN Research Forum Bronquiectasias. Introducción por Esther Barreiro
00 BRN Research Forum Bronquiectasias. Introducción por Esther Barreiro00 BRN Research Forum Bronquiectasias. Introducción por Esther Barreiro
00 BRN Research Forum Bronquiectasias. Introducción por Esther Barreiro
 

Último

Hematology and Immunology - Leukocytes Functions
Hematology and Immunology - Leukocytes FunctionsHematology and Immunology - Leukocytes Functions
Hematology and Immunology - Leukocytes FunctionsMedicoseAcademics
 
VarSeq 2.6.0: Advancing Pharmacogenomics and Genomic Analysis
VarSeq 2.6.0: Advancing Pharmacogenomics and Genomic AnalysisVarSeq 2.6.0: Advancing Pharmacogenomics and Genomic Analysis
VarSeq 2.6.0: Advancing Pharmacogenomics and Genomic AnalysisGolden Helix
 
Presentation on Parasympathetic Nervous System
Presentation on Parasympathetic Nervous SystemPresentation on Parasympathetic Nervous System
Presentation on Parasympathetic Nervous SystemPrerana Jadhav
 
The next social challenge to public health: the information environment.pptx
The next social challenge to public health:  the information environment.pptxThe next social challenge to public health:  the information environment.pptx
The next social challenge to public health: the information environment.pptxTina Purnat
 
Culture and Health Disorders Social change.pptx
Culture and Health Disorders Social change.pptxCulture and Health Disorders Social change.pptx
Culture and Health Disorders Social change.pptxDr. Dheeraj Kumar
 
Glomerular Filtration and determinants of glomerular filtration .pptx
Glomerular Filtration and  determinants of glomerular filtration .pptxGlomerular Filtration and  determinants of glomerular filtration .pptx
Glomerular Filtration and determinants of glomerular filtration .pptxDr.Nusrat Tariq
 
History and Development of Pharmacovigilence.pdf
History and Development of Pharmacovigilence.pdfHistory and Development of Pharmacovigilence.pdf
History and Development of Pharmacovigilence.pdfSasikiranMarri
 
systemic bacteriology (7)............pptx
systemic bacteriology (7)............pptxsystemic bacteriology (7)............pptx
systemic bacteriology (7)............pptxEyobAlemu11
 
Case Report Peripartum Cardiomyopathy.pptx
Case Report Peripartum Cardiomyopathy.pptxCase Report Peripartum Cardiomyopathy.pptx
Case Report Peripartum Cardiomyopathy.pptxNiranjan Chavan
 
Nutrition of OCD for my Nutritional Neuroscience Class
Nutrition of OCD for my Nutritional Neuroscience ClassNutrition of OCD for my Nutritional Neuroscience Class
Nutrition of OCD for my Nutritional Neuroscience Classmanuelazg2001
 
SWD (Short wave diathermy)- Physiotherapy.ppt
SWD (Short wave diathermy)- Physiotherapy.pptSWD (Short wave diathermy)- Physiotherapy.ppt
SWD (Short wave diathermy)- Physiotherapy.pptMumux Mirani
 
low cost antibiotic cement nail for infected non union.pptx
low cost antibiotic cement nail for infected non union.pptxlow cost antibiotic cement nail for infected non union.pptx
low cost antibiotic cement nail for infected non union.pptxdrashraf369
 
Lippincott Microcards_ Microbiology Flash Cards-LWW (2015).pdf
Lippincott Microcards_ Microbiology Flash Cards-LWW (2015).pdfLippincott Microcards_ Microbiology Flash Cards-LWW (2015).pdf
Lippincott Microcards_ Microbiology Flash Cards-LWW (2015).pdfSreeja Cherukuru
 
SGK HÓA SINH NĂNG LƯỢNG SINH HỌC 2006.pdf
SGK HÓA SINH NĂNG LƯỢNG SINH HỌC 2006.pdfSGK HÓA SINH NĂNG LƯỢNG SINH HỌC 2006.pdf
SGK HÓA SINH NĂNG LƯỢNG SINH HỌC 2006.pdfHongBiThi1
 
METHODS OF ACQUIRING KNOWLEDGE IN NURSING.pptx by navdeep kaur
METHODS OF ACQUIRING KNOWLEDGE IN NURSING.pptx by navdeep kaurMETHODS OF ACQUIRING KNOWLEDGE IN NURSING.pptx by navdeep kaur
METHODS OF ACQUIRING KNOWLEDGE IN NURSING.pptx by navdeep kaurNavdeep Kaur
 
PULMONARY EDEMA AND ITS MANAGEMENT.pdf
PULMONARY EDEMA AND  ITS  MANAGEMENT.pdfPULMONARY EDEMA AND  ITS  MANAGEMENT.pdf
PULMONARY EDEMA AND ITS MANAGEMENT.pdfDolisha Warbi
 
PULMONARY EMBOLISM AND ITS MANAGEMENTS.pdf
PULMONARY EMBOLISM AND ITS MANAGEMENTS.pdfPULMONARY EMBOLISM AND ITS MANAGEMENTS.pdf
PULMONARY EMBOLISM AND ITS MANAGEMENTS.pdfDolisha Warbi
 
Music Therapy's Impact in Palliative Care| IAPCON2024| Dr. Tara Rajendran
Music Therapy's Impact in Palliative Care| IAPCON2024| Dr. Tara RajendranMusic Therapy's Impact in Palliative Care| IAPCON2024| Dr. Tara Rajendran
Music Therapy's Impact in Palliative Care| IAPCON2024| Dr. Tara RajendranTara Rajendran
 
Introduction to Sports Injuries by- Dr. Anjali Rai
Introduction to Sports Injuries by- Dr. Anjali RaiIntroduction to Sports Injuries by- Dr. Anjali Rai
Introduction to Sports Injuries by- Dr. Anjali RaiGoogle
 
CEHPALOSPORINS.pptx By Harshvardhan Dev Bhoomi Uttarakhand University
CEHPALOSPORINS.pptx By Harshvardhan Dev Bhoomi Uttarakhand UniversityCEHPALOSPORINS.pptx By Harshvardhan Dev Bhoomi Uttarakhand University
CEHPALOSPORINS.pptx By Harshvardhan Dev Bhoomi Uttarakhand UniversityHarshChauhan475104
 

Último (20)

Hematology and Immunology - Leukocytes Functions
Hematology and Immunology - Leukocytes FunctionsHematology and Immunology - Leukocytes Functions
Hematology and Immunology - Leukocytes Functions
 
VarSeq 2.6.0: Advancing Pharmacogenomics and Genomic Analysis
VarSeq 2.6.0: Advancing Pharmacogenomics and Genomic AnalysisVarSeq 2.6.0: Advancing Pharmacogenomics and Genomic Analysis
VarSeq 2.6.0: Advancing Pharmacogenomics and Genomic Analysis
 
Presentation on Parasympathetic Nervous System
Presentation on Parasympathetic Nervous SystemPresentation on Parasympathetic Nervous System
Presentation on Parasympathetic Nervous System
 
The next social challenge to public health: the information environment.pptx
The next social challenge to public health:  the information environment.pptxThe next social challenge to public health:  the information environment.pptx
The next social challenge to public health: the information environment.pptx
 
Culture and Health Disorders Social change.pptx
Culture and Health Disorders Social change.pptxCulture and Health Disorders Social change.pptx
Culture and Health Disorders Social change.pptx
 
Glomerular Filtration and determinants of glomerular filtration .pptx
Glomerular Filtration and  determinants of glomerular filtration .pptxGlomerular Filtration and  determinants of glomerular filtration .pptx
Glomerular Filtration and determinants of glomerular filtration .pptx
 
History and Development of Pharmacovigilence.pdf
History and Development of Pharmacovigilence.pdfHistory and Development of Pharmacovigilence.pdf
History and Development of Pharmacovigilence.pdf
 
systemic bacteriology (7)............pptx
systemic bacteriology (7)............pptxsystemic bacteriology (7)............pptx
systemic bacteriology (7)............pptx
 
Case Report Peripartum Cardiomyopathy.pptx
Case Report Peripartum Cardiomyopathy.pptxCase Report Peripartum Cardiomyopathy.pptx
Case Report Peripartum Cardiomyopathy.pptx
 
Nutrition of OCD for my Nutritional Neuroscience Class
Nutrition of OCD for my Nutritional Neuroscience ClassNutrition of OCD for my Nutritional Neuroscience Class
Nutrition of OCD for my Nutritional Neuroscience Class
 
SWD (Short wave diathermy)- Physiotherapy.ppt
SWD (Short wave diathermy)- Physiotherapy.pptSWD (Short wave diathermy)- Physiotherapy.ppt
SWD (Short wave diathermy)- Physiotherapy.ppt
 
low cost antibiotic cement nail for infected non union.pptx
low cost antibiotic cement nail for infected non union.pptxlow cost antibiotic cement nail for infected non union.pptx
low cost antibiotic cement nail for infected non union.pptx
 
Lippincott Microcards_ Microbiology Flash Cards-LWW (2015).pdf
Lippincott Microcards_ Microbiology Flash Cards-LWW (2015).pdfLippincott Microcards_ Microbiology Flash Cards-LWW (2015).pdf
Lippincott Microcards_ Microbiology Flash Cards-LWW (2015).pdf
 
SGK HÓA SINH NĂNG LƯỢNG SINH HỌC 2006.pdf
SGK HÓA SINH NĂNG LƯỢNG SINH HỌC 2006.pdfSGK HÓA SINH NĂNG LƯỢNG SINH HỌC 2006.pdf
SGK HÓA SINH NĂNG LƯỢNG SINH HỌC 2006.pdf
 
METHODS OF ACQUIRING KNOWLEDGE IN NURSING.pptx by navdeep kaur
METHODS OF ACQUIRING KNOWLEDGE IN NURSING.pptx by navdeep kaurMETHODS OF ACQUIRING KNOWLEDGE IN NURSING.pptx by navdeep kaur
METHODS OF ACQUIRING KNOWLEDGE IN NURSING.pptx by navdeep kaur
 
PULMONARY EDEMA AND ITS MANAGEMENT.pdf
PULMONARY EDEMA AND  ITS  MANAGEMENT.pdfPULMONARY EDEMA AND  ITS  MANAGEMENT.pdf
PULMONARY EDEMA AND ITS MANAGEMENT.pdf
 
PULMONARY EMBOLISM AND ITS MANAGEMENTS.pdf
PULMONARY EMBOLISM AND ITS MANAGEMENTS.pdfPULMONARY EMBOLISM AND ITS MANAGEMENTS.pdf
PULMONARY EMBOLISM AND ITS MANAGEMENTS.pdf
 
Music Therapy's Impact in Palliative Care| IAPCON2024| Dr. Tara Rajendran
Music Therapy's Impact in Palliative Care| IAPCON2024| Dr. Tara RajendranMusic Therapy's Impact in Palliative Care| IAPCON2024| Dr. Tara Rajendran
Music Therapy's Impact in Palliative Care| IAPCON2024| Dr. Tara Rajendran
 
Introduction to Sports Injuries by- Dr. Anjali Rai
Introduction to Sports Injuries by- Dr. Anjali RaiIntroduction to Sports Injuries by- Dr. Anjali Rai
Introduction to Sports Injuries by- Dr. Anjali Rai
 
CEHPALOSPORINS.pptx By Harshvardhan Dev Bhoomi Uttarakhand University
CEHPALOSPORINS.pptx By Harshvardhan Dev Bhoomi Uttarakhand UniversityCEHPALOSPORINS.pptx By Harshvardhan Dev Bhoomi Uttarakhand University
CEHPALOSPORINS.pptx By Harshvardhan Dev Bhoomi Uttarakhand University
 

BRN Symposium 03/06/16 Microbiome in COPD: Pitfalls and Progress

  • 1. The Microbiome in COPD Progress and Pitfalls Sanjay Sethi MD Professor of Medicine Division Chief, Pulmonary, Critical Care and Sleep Medicine Assistant Vice President for Health Sciences University at Buffalo, SUNY ssethi@buffalo.edu
  • 2. British Hypothesis  Mucus Hypersecretion  Infective exacerbations Fletcher and Peto BMJ 1977,1:1645-8 Ciba Guest Symposium 1959, Thorax;14:286-99
  • 3.
  • 4. Learning Objectives  Does the lung microbiome change in Stable COPD?  Does the lung microbiome impact disease progression in COPD?  Does the lung microbiome change at Exacerbation and with its treatment?  Does conventional microbiology have a role in the microbiome era?
  • 5. Learning Objectives  Does the lung microbiome change in Stable COPD?  Does the lung microbiome impact disease progression in COPD?  Does the lung microbiome change at Exacerbation and with its treatment?  Does conventional microbiology have a role in the microbiome era?
  • 6. Microbiome Diversity in COPD Cabrera-Rubio J Clin Micro 2012; 50 (11):3562  Six former smokers with moderate COPD  No controls  Sputum, BAL, Bronchial biopsy and Bronchial aspirates obtained
  • 7. Microbiome diversity in COPD Erb-Downward et al PLoS ONE 6(2): e16384.
  • 8. Tissue microbiome in COPD Sze et al AJRCCM 2012,185:1073-80
  • 9. Are these Upper or Lower Airway Samples? Hilty et al, Plos ONE 5 (1): e58578 Erb-Downward et al PLoS ONE 6(2): e16384.
  • 10. Bacterial Colonization in Ex-smokers with COPD Group % positive for PPM >/=102/ml Pathogens isolated Titer 1 (ex-smokers with COPD) 34.6 % (9/26) 1) NTHI and HP 2) NTHI and SP 3) HP 4) PA 5) SA 6) NTHI 7) NTHI 8) HP 9) HP 3 x 102 2 x 102 7 x 104 2 x 104 1 x 102 6 x 102 1 x 102 1.5 x 104 5 x 105 6.5 x 105 3 x 105 2 (ex-smokers without COPD) 0% (0/20) 3 (healthy non- smokers) 6.7% (1/15) 1) HP 2 x 102 Sethi et al AJRCCM 2006, 173:991-8 • A sequential two-scope procedure was performed • The right middle lobe was lavaged with 50 x 3 ml of saline.
  • 11. Endotoxin levels in BAL in COPD Sethi et al AJRCCM 2006, 173:991-8
  • 12. Contamination of Lower Airway Specimens Sethi et al AJRCCM 2006, Charlson et al AJRCCM 2011 Unless measures are taken - to avoid scope contamination and - control for environmental contamination - the results of Bronchoscopic microbiome studies are uninterpretable
  • 13. Does the Lung Microbiome change in Stable COPD?  Yes, by conventional microbiology  Current microbiome studies are inadequate  Increase in Proteobacteria  Decrease in Diversity  Similar Community structure changes are seen in Bronchiectasis and Cystic Fibrosis
  • 14. Learning Objectives  Does the lung microbiome change in Stable COPD?  Does the lung microbiome impact disease progression in COPD?  Does the lung microbiome change at Exacerbation and with its treatment?  Does conventional microbiology have a role in the microbiome era?
  • 15. Bacterial Colonization in Ex-smokers with COPD Group % positive for PPM >/=102/ml Pathogens isolated Titer 1 (ex-smokers with COPD) 34.6 % (9/26) 1) NTHI and HP 2) NTHI and SP 3) HP 4) PA 5) SA 6) NTHI 7) NTHI 8) HP 9) HP 3 x 102 2 x 102 7 x 104 2 x 104 1 x 102 6 x 102 1 x 102 1.5 x 104 5 x 105 6.5 x 105 3 x 105 2 (ex-smokers without COPD) 0% (0/20) 3 (healthy non- smokers) 6.7% (1/15) 1) HP 2 x 102 Sethi et al AJRCCM 2006, 173:991-8 • A sequential two-scope procedure was performed • The right middle lobe was lavaged with 50 x 3 ml of saline.
  • 16. 0 10 20 30 40 50 60 70 80 90 COPD PPB+ COPD PPB- Ex-smokers Non-smokers %PMN Groups p<0.001 p<0.001 p=0.03 p=0.02 p=0.004 0 50000 100000 150000 200000 250000 300000 350000 400000 450000 PMN/ml p=0.02 p=0.007 p<0.001 COPD PPB+ COPD PPB- Ex-smokers Non-smokers Groups Sethi S et al Am J Resp Crit Care Med 2006;173:991-8. PMN, polymorphonuclear neutrophil; PBB, potentially pathogenic bacteria, including Haemophilus spp, Streptococcus pneumoniae, Moraxella catarrhalis, Staphylococcus aureus, Pseudomonas aeruginosa, and Gram-negative enteric bacteria Bacterial Colonization and Airway Inflammation in Ex-smokers with COPD
  • 17. Groups Groups 1 10 100 1000 IL-8pg/ml p=0.006 p<0.001 p<0.001 p=0.02 1 10 100 1000 10000 100000 1000000 ActiveMMP-9units/ml p=0.04 p<0.001 p=0.01 p=0.002 p=0.007 IL-8, interleukin 8; MMP-9, matrix metalloproteinase-9 Bacterial Colonization and Airway Inflammation in Ex-smokers with COPD COPD PPB+ COPD PPB- Ex-smokers Non-smokers COPD PPB+ COPD PPB- Ex-smokers Non-smokers Sethi S et al Am J Resp Crit Care Med 2006;173:991-8.
  • 18. Greater Induction of Cytokines by Proteobacteria from Dendritic Cells Larsen et al, PLoS ONE 2012, 7(2): e31976
  • 19. Potential Consequences of Altered Airway Microbiome in COPD Hogg et al, NEJM 2004, Martínez-García et al. Chest 2011
  • 20. Vicious Circle Hypothesis Initiating factors e.g. smoking, childhood respiratory disease Impaired innate lung defense Microbial Colonization Airway epithelial injury Inflammatory response Increased proteolytic activity Altered proteinase anti-proteinase balance Progression of COPD Bacterial products Acute Exacerbation Sethi and Murphy NEJM 2008
  • 21. Learning Objectives  Does the lung microbiome change in Stable COPD?  Does the lung microbiome impact disease progression in COPD?  Does the lung microbiome change at Exacerbation and with its treatment?  Does conventional microbiology have a role in the microbiome era?
  • 22. COPD Study Clinic  Aims  Dynamics of bacterial infection in COPD  Hypothesis  Acquisition of new strains of bacterial pathogens is associated with an increased risk of exacerbation  Clinic visits:  Monthly  Suspected exacerbation  At each visit:  Clinical evaluation  Serum sample  Sputum sample for quantitative bacteriology
  • 23. Naturally Occurring Exacerbations: Changes in the Microbiome -150 -100 -50 0 50 100 150 Days Relative to Exacerbation Exacerbationonset Antibiotics only Corticosteroids only Antibiotics and corticosteroids Exacerbation treatment group Huang et al, JCM, J Clin Microbiol. 2014 ;52(8):2813-23
  • 24. Changes in Microbiome at Exacerbation Huang et al, JCM, J Clin Microbiol. 2014 ;52(8):2813-23
  • 25. Bacterial Families Hang out Together Le ntisp ha erae En teroba cteriace ae Ve rru co micro bia Ve rru co micro bia su bd ivision 5 LD 1P A grou p Ch lamyd iace ae Pa rach lamyd iace ae WS3 un cla ssifie d BR C1 C ald ith rix Aquifi ca e G em m at im ona de te s G em m at im on ad et es Clo stridia ceae Clo stridia ceae Clo stridia ceae Clo stridiacea e Clostridiacea e Clostridiacea e Clostridiaceae ClostridiaceaeClostridiaceaeClostrid iace ae LachnospiraceaeLachnospiraceaeLachnospiraceaeLachnospiraceaeLachnospiraceaeLachnospiraceae gutclo ne gro up gutclo ne gro upCa tab acterCa tab acter LachnospiraceaeLachnospiraceae Lachnospiraceae Lachnospiraceae Lachnospiraceae Lachnospiraceae Lachnospiraceae Lachnospiraceae Lachnospiraceae Lachnospiraceae Lachnospiraceae Lachnospiraceae Lachnospiraceae Lachnospiraceae Lachnospiraceae Lachnospiraceae LachnospiraceaeLachnospiraceaeLachnospiraceaeLachnospiraceae Aer oc oc ca ce ae Aer oc oc ca ce ae Ae ro co cc ac ea e Car no ba cter iace ae Ae ro co cc ac ea e En teroco cc ac ea e En teroco cc ac ea e En teroco ccac ea e En teroco ccac ea e En teroco ccac ea e En ter ococcaceae En teroco cc ac ea e En teroco cc ac ea e En teroco cc ac ea e Lacto bacillac eae Lacto bacillaceae Lacto bacillaceae Lacto bacillaceae Lacto bacillaceae Lacto bacillace ae Lactobacillace ae Lac tob acillac eae Lac tobacillac eae Lac tobacillaceae Lac tobacillaceae Lac tobacillace ae Leuconostoc aceae Le ucon ostoc aceae Stre ptoc occaceae Streptococcaceae Streptococcaceae Streptococcaceae Streptococcaceae Streptococcaceae Streptococcaceae Streptococcaceae Streptococcaceae Streptococcaceae Streptococca ceae Streptococca ceae Streptococcaceae Strep tococcaceae Streptococcaceae Streptococcacea e Bac illi Stre ptococcaceae Pa eniba cillac eae Sp oro lac tob acilla ceae Ca ryo phanaceae Ba cillac ea e Ba cillac ea e Ba cillac ea e Ba cillac ea e Ba cillace ae Bac illac ea e Bac illac ea e Bac illac ea e Bac illac ea e Bac illac ea e Bac illac ea e Bac illac ea e Bac illac ea e Bac illac ea e Bac illac ea e Bac illac ea e Baci lla ce ae Baci lla ce ae Sta ph yloc oc ca ce ae Sta ph yloc oc ca ce ae Sta ph yloc oc ca ce ae Sta ph yloc oc ca ce ae Sta ph yloc oc ca ce ae Sta ph yloc oc ca ce ae Sta ph yloc oc ca ce aeSta ph yloc oc ca ce ae Sta ph yloc oc ca ce ae Baci lla ce ae Ha loba cillace ae Ha loba cillace aeBa cilla ce ae Ba cilla ce ae Bac illac ea e Ba cilla ce ae Ha loba cilla ce ae Fus oba cteriac eae Mycop lasmataceae Acholeplasmataceae Ery sipelotric haceae Ery sipelo tric haceae Erysipe lotrichaceae Erysipe lotrichaceae Clostridiaceae Clostridiaceae Clostridiaceae Clostridiaceae Clostridiaceae ClostridiaceaePeptostreptococcaceaePeptostreptococcaceaePeptostreptococcaceae ClostridiaceaeClostridiaceaeClostridiaceaePeptostreptococcaceae ClostridiaceaeClostridiaceaePeptostreptococcaceae Peptostreptoco ccaceae Peptostreptoco ccaceae Pep tostrep tococcaceae Pep tostrep tococcaceae Peptostre ptococ cac eae Pe ptoc oc c/Ac idam inoc oc c Pe ptoc c/A cid am ino co cc Pe ptococ c/A cid am ino co cc Pe ptoc oc c/A cid am ino co cc Pe pto cc/Acid am ino cocc Pe pto cc/Acid am ino cocc Firm icutes Natrono an ae robium Sy mbiob ac teria Ba cillace ae Firm icu tes Pol ya ng ia ce ae Pol ya ng ia ce ae Pol ya ng ia ce ae Pol ya ng ia ce ae Pol ya ng ia ce ae Delta pr ot eo ba cter ia Delta pr ot eo ba cter ia Delta pr ot eo ba cter ia Del ta pr ot eo ba cter ia Delta pr ot eo ba cter ia Des ulfoba cter ac ea e Syn tro ph ac ea e Deltaproteo ba cteria Des ulfobu lbac ea e De su lfo bu lbac ea e De su lfo bu lbac ea e Des ulfoba cter ac ea e Deltaproteo ba cteria D esu lfu ro m onace ae G eob ac te ra ce ae Syn trop ho ba ct er ac ea e Del ta pr ot eo ba ct er ia Syn trop ho ba ct er ac ea e Del ta pr ot eo ba ct er iaD elta pro te obact eria De su lfo ha lobiac ea e De su lfo vib rio na ce ae De su lfovib rio na ce ae Rhodocyclaceae Nitro somonadaceae Betaproteobacteria Methylophilaceae Rhodocyclaceae Rhodocyclaceae Neisseriaceae Procabacteriaceae Burkholderiaceae Ralstoniaceae Ralstoniaceae Ralstoniaceae Ralstoniaceae Oxalobacteraceae Oxalobacteraceae Oxalobacteraceae Oxalobacteraceae Oxalobacteraceae Oxalobacteraceae Oxalobacteraceae Oxalobacteraceae Burkholderiaceae Alcaligenaceae Alcaligenaceae Alcaligenaceae Gammaproteobacteria Xanthomonadaceae Xanthomonadaceae Xanthomonadaceae Xanthomonadaceae Xanthomonadaceae Legionellaceae Moraxellace ae Moraxellaceae Moraxellaceae Moraxellaceae Pseud omona dac eae Pseud omonadace ae Pseudomo nadaceae Pseudomo nadaceae Pseudomo nadaceae Ocean osp irilla cea e Pseud omona dac eae Pis cirick ettsia ceae Pis cirick ettsia ceae Ga mm aproteobacte ria Me thy loc occaceae Ga mm ap roteob acter ia Ga mm ap roteo ba cte ria Ga mm aproteobacte ria Gammaproteobacteria Halomonadaceae Alte ro m on ad ac ea e Alte ro m on ad ac ea e Pse ud oa lte ro m on ad ac ea e Alte ro m on ad ac ea eAl tero mon ad ac ea e Ps eu do altero mon ad ac ea e Alteromon ad ac ea e Alteromon ad ac ea e Alteromon ad ac ea e Alteromon ad ac ea e Alteromon ad ac ea e Alteromon ad ac ea e Alteromon ad ac ea e Al tero mon ad ac ea e Al tero mon ad ac ea e Alte ro m on ad ac ea e Alte ro m on ad ac ea e Alte ro m on ad ac ea e Alte ro m on ad ac ea e Alte ro m on ad ac ea e Alte ro m on ad ac ea e Alte ro m on ad ac ea e She wan ellace ae Alte ro m on ad ac ea e Alte ro m on ad ac ea e G am m ap ro te ob ac te ria Alte ro m on ad ac ea e Alte ro m on ad ac ea e Alte ro m on ad ac ea e Shew an el la ce ae Shew anella ce ae Shew anella ce ae G am m apro te obact eria Vibriona ce ae Vi br iona ce ae Vibrio na ce ae Vibrio na ce ae Vibrio na ce ae Pa ste urellacea e Pa ste urellacea e Pa ste urellaceae Pa ste urellacea e Pa ste ure llaceae Pa ste ure llaceae Paste ure llac eae Paste ure llac eae Paste ure llac eae Pa ste ure llaceae Pa ste ure llaceae Enterobac teriace ae Enterobac teriace ae Enterobacteriaceae Enterobacteriaceae EnterobacteriaceaeEnterobacteriaceaeEnterobacteriaceaeEnterobacteriaceaeEnterobacteriaceae Enterobacteriaceae Enterobacteriaceae Enterobacteriaceae Enterobacteriaceae Enterobacteriaceae Enterobacteriaceae Enterobacteriaceae Enterobacteriaceae Enterobacteriaceae Enterobacteriaceae Enterobacteriaceae Enterobacteriaceae Enterobacteriaceae Enterobacteriaceae Enterobacteriaceae Enterobacteriaceae Enterobacteriaceae Enterobacteria ceae Enterobacteriaceae Enterobacteriaceae Enterobacteriacea e Ente roba cteriaceae Enterobacteria ceae Enterobacteriaceae Enterobacteriaceae Enterobac teriace ae Enterobac teriace ae Gammaproteobacteria Enterobacteriaceae Enterobacteriaceae Enterobacteriaceae Enterobacteriaceae Enterobacteriaceae Enterobacteriaceae Enterob acte riaceae Enterob acte riaceae Ente roba cteriaceae Enterobacteriaceae Enterobacteria ceaeEnterobacteriaceaeEnterobacteriaceaeEnterobacteriaceae Enterobacteriaceae Ente robacteriaceae Enterobacteria cea e Entero bac teriace ae X6 04 12 .2 Ae romon ad ac ea e Ae romon ad ac ea e S3 92 32 .2 Ae romon ad ac ea e Ae romon ad ac ea e Ch romatiac ea e Gammaproteobacteria Coxiellaceae Coxiellaceae Coxiellaceae Thiotrichaceae Thiotrichaceae Chromatiaceae Gam map roteobacteria Ro seococcaceae Alph ap roteo ba cte ria Rickettsia ceae Rickettsia ceae Ca ediba cte rac eae Alp hapro teo bacte ria Alp hapro teo bacte ria Rhodocyclaceae Caulobac terace ae Caulobac tera cea e Cau lobacteraceae Cau loba cteraceaeCaulobactera cea e Alp hapro teo bacte ria Bra dyrhizobiaceae Bra dyrhizobiaceae Ac idob ac teria Acido ba cter iace ae Acido ba cter iace ae Acido ba cter iace ae Acido ba cter iace ae Acido ba cter ia Acido ba cter iace ae Acido ba cter ia ce ae Nitros pina ce ae Ac idob ac teria ce ae Ac idob ac teria De lta proteo ba cteria De lta proteo ba cteria NC 10 −2Un cla ss ifie d Leptospiraceae Leptospiraceae Spirochaetaceae Spirochaetaceae Spirochaetaceae Spirochaetaceae Spirochaetaceae Spirochaetaceae Chlorobi Cren otrichace ae Ba cte roide tes Ba cte roide tes Sp hin go ba cte ria Ba cte roide tes Ba cte roide tes Ba cte roidetes Ba cte roidetes Ba cte roide tes Rik enella cea e Bacte roidetes Porph yro mo nadaceae Ba cte roidaceae Ba cte roidaceae Bacteroid etes Bacteroid ete s Flavob acteria ceae Flavob acteria cea e Blattab acteria cea e SphingobacteriaFlex ibac teraceae Flam meo virgaceae Flexiba cteraceae CrenotrichaceaeCrenotrich aceaeCrenotrichaceaeCren otrichace ae Helicobacteraceae Helicobacteraceae Epsilonproteobacteria Helicobacteraceae Campylobacteraceae mgA−2 mgA−1 TM7−3 CyanobacteriaChloroplasts Chloroplasts Chloroplasts Cop ro th er m ob ac te ria Syn er gi st es Syn er gi st es Syn er gist es Syn er gi stesOP9 Deh aloc oc co idet es Deh aloc oc co idetes Deh aloc oc co idetes Ana er olinea e Chlor of lexi Cellulom on ad ac ea e M icro co cc ac ea e M icro co cc ac ea e Acido ba ct er ia Act in om yc et ac ea e Bifido ba ct er ia ce ae Bifido ba ct er ia ce ae Bifi do ba ct er ia ce ae Acido ba cter ia Acido ba cter ia Cor ioba cter iace ae Rub ro ba cter ac ea e Ac idob ac teria 0.01 Classes (tree branches): Gammaproteobacteria Verrucomicrobiae Chlamydiae Aquificae gut clone group Catabacter Bacilli Fusobacteria Mollicutes Symbiobacteria Deltaproteobacteria Betaproteobacteria Alphaproteobacteria Acidobacteria N C 10− 2 Spirochaetes Sphingobacteria Bacteroidetes Flavobacteria Epsilonproteobacteria m gA − 1 T M 7− 3 Cyanobacteria OP9 Actinobacteria Enterobacteriaceae Pasteurellaceae (Haemophilus-related) Pseudomonadaceae Moraxellaceae Oxalobacteraceae (Betaproteobacteria) Lactobacillus spp. Streptococcaceae (Lactobacillales) Helicobacter Campylobacter (Epsilonproteobacteria) Deltaproteobacteria Staphylococcus spp. Clostridiaceae/Lachnospiraceae (Clostridia) Bacillaceae Abundance Higher Lower Positive correlation Negative correlation Huang et al, JCM, J Clin Microbiol. 2014 ;52(8):2813-23
  • 26. Antibiotics and Steroids have Differential Effects on the Microbiome in AECOPD Positive changes in relative abundance (log2) indicate an increase in the latter time point compared. Huang et al, JCM, J Clin Microbiol. 2014 ;52(8):2813-23
  • 27. MAESTRAL Study: Clinical Failure Rates with Oral Corticosteroid use 0 5 10 15 20 25 30 35 40 During therapy EOT 4 weeks post- therapy 8 weeks post- therapy Clinicalfailure(%ofpatients) Sethi et al, Infection 2016
  • 28. Changes in Airway Microbiome after Rhinovirus inoculation Molyneaux; et al, Am J Respir Crit Care Med 188, 1224-1231. *P < 0.001
  • 29. Control: no significant differences Distribution of bacterial phyla at each time point after rhinovirus (RV) inoculation. Molyneaux et al, Am J Respir Crit Care Med 188, 1224-1231. COPD: significant increases in Proteobacteria (dark blue) were observed on Day 15 (P = 2.2 × 10–16).
  • 30. Bacterial Load (16s) and Inflammatory Changes following Rhinovirus Infection Molyneaux et al, Am J Respir Crit Care Med 188, 1224-1231. p=0.08 p=0.0001 p=0.007 p=0.045p=0.001 p=0.07
  • 31. Learning Objectives  Does the lung microbiome change in Stable COPD?  Does the lung microbiome impact disease progression in COPD?  Does the lung microbiome change at Exacerbation and with its treatment?  Does conventional microbiology have a role in the microbiome era?
  • 32. TMI
  • 33. Losing the Trees in the Forest
  • 34. Species vs Strain level Differentiation Han et al Thorax 2013 Sethi et al NEJM 2008
  • 35. NTHI Colonization vs Exacerbation strains •10 exacerbation strains •7 colonization strains •In vivo mouse model •In vitro respiratory epithelial cell line Chin et al AJRCCM 2005
  • 36. Does Conventional Microbiology have a Role in the Microbiome Era?  Identifying a pathogen by sequence is the first step  Immune and inflammatory consequences of putative pathogens need to be determined  Ability to manipulate the pathogen in culture is essential  Vaccine development  Pathogen virulence
  • 37. Conclusions  The ability to assess the lung microbiome could radically change our understanding of lung disease and lung infection  COPD and COPD exacerbations are clearly associated with changes in the lung microbiome  Restoring the healthy lung microbiome could make a significant difference in COPD management  Maybe, the British were right all the time!
  • 38. Acknowledgments  Co-Investigators  Tim Murphy  Charles Berenson  Karin Provost  Ilya Berim  Study coordinators  Nancy Evans  Karen Eschberger  Jane Maloney  Ellana Eberhardt  Laboratory personnel  Catherine Wrona  Lori Grove  Phyllis Lobbins  Regina Clare  Collaborators  Yvonne Huang (UCSF)  U of Iowa